Compact Radio Sources and Nuclear Activity in Seyfert Galaxies

Using recent high-resolution radio observations of a large sample of Seyfert galaxies (Roy et al. 1994), we analyze the relations between the compact radio core emission and several nuclear and host galaxy properties. Seyfert nuclei hosted in early-type galaxies or in object with nearby companions show stronger radio cores than the norm. Radio core emission show some correlation with total radio emission and with tracers of nuclear activity (mid-IR, hard X-ray and narrow-line emissions). This favours the view that Seyfert radio cores are powered by AGN rather than by radio supernovae.Comment: 20 pages, latex file with macros included, 7 figures and 6 tables (automatically included

Constraints on Dark Energy state equation with varying pivoting redshift

We assume the DE state equations w(a) = w_0+w_a(a_p-a), and study the dependence of the constraints on w_0 and w_a coefficients on the pivoting redshift 1+z_p=1/a_p. Coefficients are fitted to data including WMAP7, SNIa (Union 2.1), BAO's (including WiggleZ and SDSS results) and H_0 constraints. The fitting algorithm is CosmoMC. We find specific differences between the cases when neutrino mass is allowed or disregarded. More in detail: i) The z_p value yielding uncorrelated constraints on w_0 and w_a is different in the two cases, holding ~0.25 and ~0.35, respectively. (ii) If we consider the intervals allowed to w_0, we find that they shift when z_p increases, in opposite directions for vanishing or allowed neutrino mass. This leads to no overlap between 1sigma intervals already at z_p >~0.4. (iii) The known effect that a more negative state parameter is required to allow for neutrino mass displays its effects on w_a, rather than on w_0. (iv) The w_0-w_a constraints found by using any pivot z_p can be translated into constraints holding at a specific z_p value (0 or the z_p where errors are uncorrelated). When we do so, error ellipses exhibit a satisfactory overlap.Comment: 13 pages, 7 figures, 2 table

Good news or bad news, which do you want first? The importance of the sequence and organization of Information for financial decision-making: a neuro-electrical imaging study

Investment decisions are largely based on the information investors received from the target firm. Thaler introduced the hedonic editing framework, in which suggests that integration/segregation of information influence individual's perceived value. Meanwhile, when evaluating the evidence and information in a sequence, order effect and biases have been found to have an impact in various areas. In this research, the influence of the Organization of Information (Integration vs. Segregation) and the Sequence of Information (Negative-Positive order vs. Positive-Negative order) on individual's investment decision-making both at the behavioral level (decision) and neurometrix level (measured by an individual's emotion and Approach Withdraw tendency) was assessed for the three groups of information: a piece of Big Positive Information and a piece of Small Negative Information, a piece of Big Negative Information and a piece of Small Positive Information, and a piece of Small Negative information. The behavioral results, which are an individual's final investment decision, were consistent for all three scenarios. In general, individuals will invest more/retire less when receiving two pieces of information in a Negative-Positive order. However, the neurometric results (Emotional Index, Approach Withdraw Index and results from LORETA) show differences among information groups. An effect of the Sequence of Information and the Organization of Information was found for the different scenarios. The results suggest that in the scenarios that involve large-scale information, the organization of information (Integration vs. Segregation) influences the emotion and Approach Withdraw tendency. The results of this investigation should provide insight for effective communication of information, especially when large-scale information is involved

Low dose infliximab for prevention of postoperative recurrence of crohn's disease: Long term follow-up and impact of infliximab trough levels and antibodies to infliximab

Objective In patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels, infiximab antibodies, and might loose response to therapy. To verify this hypothesis infliximab pharmacokinetics and clinical/endoscopic response were checked in a group of patients treated in the long term with low infliximab doses. Design Infliximab antibodies, infliximab levels, highly-sensitive CRP and fecal calprotectin were measured during the 8-week interval in 5 consecutive patients in clinical (Crohn's Disease Activity Index < 150) and endoscopic (Rutgeerts scores 0-1) remission after one year of therapy with infliximab 3 mg/Kg. For comparison with reported standards, infliximab pharmacokinetics and inflammatory parameters were also tested in 6 Crohn's disease patients who did not undergo surgery and who were in clinical remission while on infliximab 5 mg/ Kg. Patients on low infliximab dose also underwent colonoscopy after 18 additional months of therapy. Results Highly sensitive CRP and fecal calprotectin increased in all patients during the 8-week interval. Infliximab trough levels were lower in patients treated with the low dose compared to controls (mean\ub1SE: 2.0\ub10.3 vs 4.75\ub10.83 \uceg/mL respectively p<0.05). Infliximab antibodies were present in two of the subjects treated with low infliximab dose and in none of the controls. However, in low dose-treated patients after 18 additional months of therapy endoscopy continued to show mucosal remission and none of them developed clinical recurrence or side effects. Conclusions Patients treated with low infliximab doses had lower trough levels compared to patients treated with 5 mg/Kg and some developed antibodies to infliximab. However, low infliximab doses sustained clinical and endoscopic remission for a total of 30 months of treatment